早上8点刚过，位于湖南湘江新区的华曙高科增材制造研发制造总部基地里，3D打印机"嗡嗡"作响，打印舱内正 逐层铺粉、烧结，一批复杂的航空部件在数小时内成形，相比传统工艺制作，3D打印在设计自由度、性能、减重 上都实现了质的"飞跃"。 这一场景映射出湖南民营经济结构发生的深层变化。如果十多年前提起湖南民企，人们第一反应是"敢闯敢拼，制 造做得好"；而如今，无论是高端装备制造、生物医药，还是新消费化妆品，年轻一代企业家们的产品往往伴随研 发、专利、试验和配方打磨而来。 技术与创新正成为湖南民企看得见的"硬能力"。 2025年，湖南民营企业数量已占全省企业总量的九成以上，民营经济贡献全省60%左右的GDP，在战略性新兴产 业和未来产业布局中民企的身影更加密集。可贵的是，这类创新不是口号式，也不是政策驱动式，而是从企业内 部长期形成的专业判断、技术积累和工艺自信。 （来源：统战新语） 湖南新生代民营经济的成长轨迹：以技术为根立身，以专精立业扎根，以融合拓局生长。 "湖南民企不都是拼市场，很多人是从工厂和研发体系里成长起来的。"长沙一位科技企业创始人说道。从产业推 进的视角来看，一批产业样本正呈现出三条鲜明路径：从0到1 ...

ZG-002 片当前给药剂量、频率以及给药周期下安全性和耐受性良好，药代动力学特征清晰明确。ZG- 002 目前拟用于治疗中重度斑块状银屑病，有望成为新一代安全性更高、疗效更好的银屑病治疗药物， 并有潜力拓展到其他的自身免疫性疾病的临床应用。 公司通过控股子公司致根医药持续加大创新药研发投入。除ZG-002 外，ZG-001（抗抑郁药）已完成1 期临床试验，安全性优异，正在开展2a 期临床试验，公司与临床中心正在积极推进各项工作，预计将 于2026 年H1读出数据，验证疗效。 以湖南省天玑珍稀中药材发展有限公司为项目平台开展的ZY 系列濒危动物药材替代品各个项目的研究 工作稳步推进。其中，ZY022 项目预计年内完成IND 申请，进入1 期临床试验。 风险提示：行业竞争加剧风险、政策风险、研发不及预期风险、市场开拓不及预期风险等。 事件：公司发布公告，参股公司收到ZG-002 片Ⅰ期临床研究报告。ZG-002（抗自身免疫药，TYK2 变 构抑制剂）1 期临床试验已于近期完成，本次临床试验的目的主要是评估ZG-002 片在健康成年受试者 中的安全性和耐受性、药代动力学特征及食物影响等。 研究结果表明，ZG-00 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688799 证券简称：华纳药厂 公告编号：2026-003 湖南华纳大药厂股份有限公司 自愿披露关于参股公司收到ZG-002片Ⅰ期临床研究报告的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）参股公司上海致根医药科技有限公司（以下简称"致 根医药"）自主研发的ZG-002片在国家药品监督管理局同意下开展Ⅰ期临床试验已于近期完成，并于近 期收到临床研究报告。现将相关情况公告如下： 三、风险提示 临床前研究表明，ZG-002为强效高选择性的TYK2变构抑制剂，在体外药理学研究中表现出较优的 TYK2抑制活性以及较高的选择性；在经典动物银屑病药效模型中，ZG-002均展现出良好的银屑病治疗 效果。在具有良好体内外活性的同时，ZG-002还表现出优异的代谢性质及安全性。上述研究结果表 明，ZG-002有望成为新一代安全性更高、疗效更好的银屑病治疗药物，并有潜力拓展到其他的自身免 疫性疾病的临床应用。 二、本次Ⅰ期临床研究 ...

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

ZG-002是致根医药自主开发的具有全新结构的新型抗自身免疫性疾病的药物，属于1类新药。ZG-002目 前拟用于治疗中重度斑块状银屑病。本次临床试验的目的主要是评估ZG-002片在健康成年受试者中的 安全性和耐受性、药代动力学特征及食物影响等。ZG-002片当前给药剂量、频率以及给药周期下安全 性和耐受性良好，药代动力学特征清晰明确。本研究已获得的临床数据可支持后续在患者人群中进一步 开展其他探索性的临床研究。 华纳药厂(688799.SH)发布公告，公司参股公司上海致根医药科技有限公司(简称"致根医药")自主研发的 ZG-002片在国家药品监督管理局同意下开展Ⅰ期临床试验已于近期完成，并于近期收到临床研究报 告。 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2026-003 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 湖南华纳大药厂股份有限公司（以下简称"公司"）参股公司上海致根医药 科技有限公司（以下简称"致根医药"）自主研发的 ZG-002 片在国家药品监督 管理局同意下开展Ⅰ期临床试验已于近期完成，并于近期收到临床研究报告。现 将相关情况公告如下： 一、药物的基本情况 ZG-002 是致根医药自主开发的具有全新结构的新型抗自身免疫性疾病的药 物，属于 1 类新药。ZG-002 目前拟用于治疗中重度斑块状银屑病。 临床前研究表明，ZG-002 为强效高选择性的 TYK2 变构抑制剂，在体外药 理学研究中表现出较优的 TYK2 抑制活性以及较高的选择性；在经典动物银屑病 药效模型中，ZG-002 均展现出良好的银屑病治疗效果。在具有良好体内外活性 的同时，ZG-002 还表现出优异的代谢性质及安全性。上述研究结果表明，ZG-002 有望成为新一代安全性更高、疗效更好的银屑病治疗药物，并有潜力拓展到其他 的自身免疫性疾病 ...

临床前研究表明，ZG-002 为强效高选择性的 TYK2 变构抑制剂，在体外药理学研究中表现出较优的 TYK2 抑制活性以及较高的选择性；在经典动物银屑病药效模型中，ZG-002 均展现出良好的银屑病治 疗效果。在具有良好体内外活性的同时，ZG-002 还表现出优异的代谢性质及安全性。上述研究结果表 明，ZG-002有望成为新一代安全性更高、疗效更好的银屑病治疗药物，并有潜力拓展到其他的自身免 疫性疾病的临床应用。 ZG-002是致根医药自主开发的具有全新结构的新型抗自身免疫性疾病的药物，属于1类新药。ZG-002目 前拟用于治疗中重度斑块状银屑病。 格隆汇2月5日丨华纳药厂(688799.SH)公布，公司参股公司上海致根医药科技有限公司自主研发的ZG- 002片在国家药品监督管理局同意下开展Ⅰ期临床试验已于近期完成，并于近期收到临床研究报告。 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its associate company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has completed Phase I clinical trials for ZG-002, a novel drug for autoimmune diseases, with the approval of the National Medical Products Administration [1] Group 1: Clinical Trial Details - ZG-002 is a first-in-class new drug developed by Zhigen Pharmaceutical, currently intended for the treatment of moderate to severe plaque psoriasis [1] - The primary objective of the clinical trial was to evaluate the safety, tolerability, pharmacokinetics, and food effects of ZG-002 in healthy adult subjects [1] - The trial results indicate that ZG-002 has good safety and tolerability under the current dosing regimen, with clear pharmacokinetic characteristics [1] Group 2: Future Research Implications - The clinical data obtained from this study supports the further exploration of ZG-002 in subsequent clinical research involving patient populations [1]

华纳药厂公告，公司参股公司致根医药自主研发的ZG-002片Ⅰ期临床试验已完成。ZG-002是具有全新 结构的新型抗自身免疫性疾病的药物，拟用于治疗中重度斑块状银屑病。临床试验结果显示，ZG-002 片在探索剂量范围内单次和多次给药后安全性和耐受性良好，未发生严重不良事件。药代动力学特征清 晰明确，血药浓度和暴露量均随给药剂量的增加而增加。试验结果显示IFN-γ水平随着药物暴露量的增 加而下降，提示ZG-002对中重度银屑病可能具有治疗潜力。 ...

Core Viewpoint - Warner Pharmaceutical experienced a decline in stock price and trading volume, with significant net financing outflows on January 29, indicating potential investor caution [1]. Group 1: Financing and Trading Data - On January 29, Warner Pharmaceutical's stock fell by 0.41%, with a trading volume of 192 million yuan [1]. - The financing buy-in amount for the day was 18.32 million yuan, while the financing repayment was 42.29 million yuan, resulting in a net financing outflow of 23.97 million yuan [1]. - As of January 29, the total financing and securities lending balance for Warner Pharmaceutical was 252 million yuan, with the financing balance accounting for 3.98% of the circulating market value, which is below the 50th percentile level over the past year [1]. Group 2: Company Overview and Financial Performance - Warner Pharmaceutical, established on April 30, 2001, and listed on July 13, 2021, is located in Changsha, Hunan Province, and specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1]. - The company's revenue composition includes 73.19% from formulation products, 25.22% from raw materials and intermediates, 1.52% from technical services, 0.06% from plant extracts and food, and 0.01% from other sources [1]. - For the period from January to September 2025, Warner Pharmaceutical reported a revenue of 1.086 billion yuan, reflecting a year-on-year growth of 1.55%, and a net profit attributable to shareholders of 207 million yuan, marking a year-on-year increase of 30.75% [2]. Group 3: Shareholder and Dividend Information - As of September 30, 2025, the number of shareholders for Warner Pharmaceutical was 6,416, a decrease of 11.83% from the previous period, while the average circulating shares per person increased by 13.42% to 20,467 shares [2]. - The company has distributed a total of 291 million yuan in dividends since its A-share listing, with 225 million yuan distributed over the past three years [3]. - Among the top ten circulating shareholders, Anxin Medical Health Stock A holds 1.2294 million shares, remaining unchanged from the previous period, while China Europe Enjoy Life Mixed A has entered the list as a new shareholder with 1.0891 million shares [3].